The Efficacy of Cladribine (2-CdA) in Advanced Systemic Mastocytosis

Grzegorz Helbig1 • Anna Koclega1 • Władysław B. Gawel2 • Martyna Włodarczyk2 • Marek Rodzaj3 • Anna Łabeź3 • Iwona Hus4 • Małgorzata Rażyń3

Abstract Systemic mastocytosis (SM) is a rare clonal disorder with multi-organ involvements and shortened life expectancy. To date, no curative treatment for SM exists. Cladribine (2-CdA) is a purine analogue showing activity against neoplastic mast cells and its use was found to be effective in some patients with SM. Nine patients (six males and three females) with advanced SM at median age of 63 years (range 33–67) who received at least one course of 2-CdA were included in a retrospective analysis. Study patients were classified as having aggressive SM (ASM; n = 7) and SM with an associated hematological neoplasm (SM-AHN; n = 2). The “C” findings were as follows: (1) absolute neutrophil count (ANC) < 1 × 10^9/l (n = 1) and/or hemoglobin level < 10 g/dl (n = 4) and/or platelet count < 100 × 10^9/l (n = 4); (2) hepatomegaly with ascites (n = 4); (3) skeletal involvement (n = 2); (4) palpable splenomegaly with hypersplenism (n = 3) and (5) malabsorption with weight loss (n = 5). Treatment consisted of 2-CdA at dose 0.14 mg/kg/day intravenously over a 2-h infusion for 5 consecutive days. Median dose per cycle was 45 mg (range 35–60). Median number of cycles was 6 (range 1–7). Overall response rate (ORR) was 66% (6/9 pts) including three partial responses and three clinical improvements. ORR was 100% and 66% for SM-AHN and ASM, respectively. Median duration of response was 1.98 years (range 0.2–11.2). At the last contact, five patients died, four have little disease activity, but remain treatment-free. 2-CdA seems to be beneficial in some patients with SM, however the response is incomplete.

Keywords Aggressive systemic mastocytosis • Cladribine • Systemic mastocytosis with an associated hematological neoplasm • KITD816V • Response

Introduction

Systemic mastocytosis (SM) is a rare and complex disease resulting from a clonal proliferation of abnormal mast cells which may accumulate in various organs. Clinical manifestations are variable ranging from pure cutaneous involvement (usually in childhood) to aggressive neoplasm with multi-organ dysfunction and shortened survival (in adults). According to the criteria of World Health Organization (WHO), indolent and advanced variants of SM exist. The indolent form (ISM) is characterized by slow disease course, low mast cell burden and relatively good prognosis. Most patients with ISM do not require cytoreductive therapy. Conversely, the advanced variant has poor prognosis with reduced survival. It includes aggressive SM (ASM), mast cell leukemia (MCL) and SM with an associated hematologic neoplasm (SM-AHN). Patients within this category have at least one “C” finding which reflects tissue damage by mast cells and they require cytoreductive therapy to decrease or reverse organ dysfunction [3, 9, 12, 14].
The diagnosis of SM can be made using WHO criteria. Briefly, the diagnostic procedure starts with bone marrow biopsy or other extra-cutaneous organs. The other tests include mast cell immunophenotyping, a molecular study towards the presence of the \( \text{KIT} \text{D816V} \) mutation and the measurement of serum tryptase levels [9].

Cytoreductive therapy is recommended for patients with advanced SM (advSM) due to the frequent presence of life-threatening organ dysfunction and shortened life expectancy. The therapeutic approach for SM-AHN is especially challenging as one has to decide which disease component (AHN or SM) requires more immediate treatment [6].

An off-label use of cladribine (2-CdA) remains a mainstay of therapy for advSM. Cladribine is a purine analogue that shows in vitro and in vivo inhibitory effect on neoplastic mast cells. Its mechanism of action does not involve tyrosine kinase inhibition therefore it causes apoptosis in mast cells independently of the presence of the \( \text{KIT} \text{D816V} \) mutation. The drug is generally well tolerated, however its use may cause prolonged myelo- and immunosuppression with subsequent occurrence of opportunistic infections [5].

Herein, we report on our experience with cladribine in nine patients with advSM.

Material

Patients and Methods

The study patients were identified through the use of our institutional database of medical records. The diagnosis of SM was based on criteria outlined in the 2008 World Health Organization (WHO) document [9]. Trephine biopsy with tryptase, CD25 and CD117 immunostaining as well as immunophenotyping studies using monoclonal antibodies against CD2/CD25/CD117 antigens were performed on bone marrow cells. Serum tryptase levels were assessed using Uni-CAP-Tryptase fluoroimmunoassay (Pharmacia & Upjohn, Uppsala, Sweden; \( N < 11.4 \text{ ng/ml} \)). The abovementioned tests were carried out before 2-CdA initiation and then repeated after treatment completion for response assessment. Identification of the \( \text{KITD816V} \) mutation was done on peripheral blood or bone marrow cells using allele-specific polymerase chain reaction (PCR). Data on cytogenetic results were reported only for three patients as dry aspirates were present in the remaining thus metaphases were not obtained. Data were collected between 2008 and 2018. All patients provided an informed consent in accordance with the Declaration of Helsinki.

Treatment

The main indication for treatment was the presence of at least one C-finding [1]. Treatment consisted of 2-CdA (Biodribin, Institute for Biotechnology and Antibiotics, Warsaw, Poland) at dose 0.14 mg/kg/day intravenously over a 2-h infusion for 5 consecutive days. The cycles were repeated every 4–6 weeks depending on decision of treating physician. All patients received prophylactically cotrimoxazole, fluconazole and acyclovir.

Response Assessment

Response assessments were performed after completion of three and six cycles of 2-CdA and were based on consensus criteria proposed by International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) [8].

Statistics

The probability of overall survival (OS) was estimated using the method of Kaplan and Meier.

Results

Nine patients (six males and three females) with advSM at median age of 63 years at diagnosis (range 33–67) who received at least one course of 2-CdA were included in a retrospective study. Males were older than females (65 years vs 37 years; \( p = 0.06 \)). The patients were classified as having ASM (\( n = 7 \)) and SM-AHN (\( n = 2 \)). The latter variant depicted myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML). Median white blood cell (WBC) and eosinophil counts were within normal range whereas median hemoglobin and platelet counts were lower than normal (9.8 g/dl and 144 \( \times 10^9/\text{l} \), respectively). Median alkaline phosphatase level was mildly increased (125 IU/l; normal range 32–92) whereas median albumin level was within normal range (39 g/l; normal range 35–52 g/l). Details were shown in Table 1.

Serum tryptase levels were increased in all study patients; and were above 200 ng/ml in 44% of them. Flow cytometry tests detected the presence of abnormal CD2+/CD25+/CD117+ cells in marrow aspirate in all but two. 67% of the study population demonstrated the presence of the \( \text{KITD816V} \) mutation. No patient with detectable \( \text{FIP1L1-PDGFRA} \) fusion gene was found. Karyotype was available only for three patients; and was diploid in two and one patient had trisomy of chromosome 8.
The "C" findings being the indication for treatment initiation were as follows: (1) absolute neutrophil count (ANC) $< 1 \times 10^9/l$ ($n = 1$) and/or hemoglobin level $< 10$ g/dl ($n = 4$) and/or platelet count $< 100 \times 10^9/l$ ($n = 4$); (2) hepatomegaly with ascites ($n = 4$); (3) skeletal involvement ($n = 2$); (4) palpable splenomegaly with hypersplenism ($n = 3$) and (5) malabsorption with weight loss ($n = 5$). The most frequent mediators release symptoms included fatigue (62%), pruritus (37%), abdominal pain (37%) and flush (25%). More than 60% of patients had at least one "B" symptom at diagnosis (fever, night sweats, weight loss). On physical examination all study patients demonstrated splenomegaly, whereas hepatomegaly was present in 77% of them. Urticaria pigmentosa was present in 55% of study cases. Three patients had lymphadenopathy.

All patients received 2-CdA intravenously for 5 consecutive days. Median dose per cycle was 45 mg (range 35–60). Median number of cycles was 6 (range 1–7). The interval between cycles was 28 days, except two patients who received only one cycle of 2-CdA (discontinued due to disease progression). In general, treatment with 2-CdA was well tolerated with no grade 3/4 non-hematological adverse events. One patient had fever with upper respiratory tract infection during the first 2-CdA cycle. Blood culture was negative and infection resolved after the treatment with empirical antibiotics. The other patients remained infection-free during the whole therapy. One patient developed asymptomatic grade 4 neutropenia after the first 2-CdA treatment, but it resolved rapidly after five doses of granulocyte colony-stimulating factor (G-CSF). None of the remaining patients had grade 3–4 neutropenia during the treatment, however grade 2 neutropenia was common during the 2-CdA treatment. Only two patients developed grade 2 thrombocytopenia and it remained stable throughout the whole treatment. None of the patients required platelet transfusions.

Overall response rate (ORR) was 66% (6/9 pts) including three partial responses (PR) and three clinical improvements (CI). ORR was 100% and 66% for SM-AHN and ASM, respectively. Median duration of response was 1.98 years (range 0.2–11.2). Among six responders, three patients progressed and two of them eventually died. One patient is alive more than 2 years from 2-CdA completion. Three other responders did not progress, however one of them died due to unclear neurological complications.

Clinical improvements were mainly observed in terms of hematological parameters (increase in ANC and/or hemoglobin and/or platelet count) and hepatosplenomegaly. There was no resolution of skin changes and lymphadenopathy. Mediators release symptoms decreased in most patients. A decrease of serum tryptase levels was observed in all patients. Mast cell infiltration in bone marrow trephine also decreased after therapy, however by less than 50% when compared with treatment initiation. At the last contact, five patients died, four remain alive.

Among expired patients, one underwent allogeneic stem cell transplantation with subsequent steroid-resistant graft versus host disease. The other patients expired due to different causes: unclear neurological complications with
paraparesis \( (n = 1) \), transformation to chemo-resistant acute myeloid leukemia \( (n = 1) \), progressive mastocytosis \( (n = 2) \).

Four living patients have little disease activity (PR; \( n = 2 \) and CI; \( n = 2 \)) and remain treatment-free after median of 2.8 years (range 0.9–11.2) after 2-CdA completion. Table 2.

**Discussion**

The decision whether to treat or not a patient with 2-CdA must be preceded by careful determination of risk-versus-benefit ratio. Nevertheless, it seems reasonable to offer this agent for patients with advanced SM in whom survival is reduced due to multi-organ involvements [1]. The first report on the efficacy of 2-CdA in a patient with advSM resistant to interferon \( \alpha \) has been published by Tefferi et al. almost 20 years ago. The treatment resulted in complete resolution of skin changes and marked reduction of mast-cell infiltration in bone marrow [13]. Since that time several study groups presented their data on efficacy and safety of 2-CdA, however different variants of mastocytosis were evaluated. In fact, when we narrow the analysis only to patients with advSM, the number of patients treated with 2-CdA was relatively small. Following the successful Tefferi’s case report [13], ten patients with SM received 2-CdA in a Kluin-Nelemans study [10], but only six of them met the criteria of advanced disease (either SM-AHN or ASM). Nevertheless, all patients responded to cyto-reductive therapy in terms of organ involvements, hematological and biochemical parameters as well as mediator-release symptoms, however no patient achieved complete remission. The time to best response took several months, but response duration was not provided. Side effects resulted mainly from bone marrow suppression and were manageable. Sixteen patients with advanced SM received 2-CdA in Mayo Clinic with ORR rate of 50% and 55% in ASM and SM-AHN, respectively. Median duration of response was 11 months. The presence of circulating immature progenitors was associated with inferior response in multivariate analysis [11]. The largest series to date on 2-CdA in mastocytosis has been reported by French Group. The study evaluated 68 patients (38 with ISM and 32 with advanced SM). Patients received median of four courses of 2-CdA with ORR of 50% for those with advanced disease (ASM-43% and SM-AHN-59%). Of note is that complete responses have not been achieved. Response duration exceeded 2 years and side effects were typical of those for 2-CdA [4].

Our results seem to confirm those of other study groups. Of note is that 2-CdA dose within all studies was uniform and side effects were typical of this agent. Nevertheless, the major concern of 2-CdA use is related to immunosuppressive and myelosuppressive toxicity. Almost 50% of the French patients developed grade 3 or 4 neutropenia after at least one course of 2-CdA. Moreover, 83% had grade 3/4 lymphopenia. One patient required allogeneic

| Table 2 Response to treatment with cladribine in advanced systemic mastocytosis |
|-----------------------------------------------|
| Parameter                                      | Result                  |
| Number of cladribine cycles (median, range)   | 6 (1–7)                |
| Median dose of cladribine per cycle (mg)      | 45 (35–60)             |
| Response to cladribine (ORR;%)                | 67                      |
| Clinical improvement                          | 3                       |
| Partial response                              | 3                       |
| Stable disease                                | 1                       |
| Disease progression                           | 2                       |
| Median duration of response (years); (median, range) | 1.45 (0.2–11.2) |
| Outcome                                       |                         |
| Death \( (n;\%) \) due to                     | 5 (56)                 |
| Transplant complications                      | 1                       |
| Unknown (probably neurological infection)      | 1                       |
| Transformation into acute myeloid leukemia    | 1                       |
| Mastocytosis resistant to therapy              | 2                       |
| Alive \( (n;\%) \)                            | 4 (44)                 |
| OS at 1 year (%)                              | 64                     |
| OS at 3 years (%)                             | 38                     |

**ORR** overall response rate, **OS** overall survival
stem cell transplantation due to prolonged pancytopenia. Infectious complications were demonstrated for 22% during the treatment and 9% of patients developed late opportunistic infections. Two solid tumors were observed after long-term follow-up [4]. A fatal case of progressive multifocal leukoencephalopathy (PML) after 2-CdA for mastocytosis as a consequence of prolonged lymphopenia has been recently published [2].

Overall response rates were comparable between our study and those presented by others [4, 10, 11]. Of note is that different response criteria have been used. ORR for the entire cohort was 66%, with ORR of 100% for SM-AHN and 66% for ASM. However, it should be mentioned that only one patient met PR criteria, and no patient achieved CR. Most patients demonstrated clinical improvements with relatively short-term duration. Death rate exceeded 50% after 2 years of follow-up. Interestingly, one patient transformed to chemo-resistant acute myeloid leukemia shortly after 2-CdA. One patient died from unclear neurological complications (PML?), but detailed diagnosis was not performed. In contrary to other studies [4, 10, 11] we did not observe grade 3 or 4 side effects on 2-CdA.

Of note is, that the KIT D816V mutation was detected in 67% of our examined patients and all those patients were tested from bone marrow sample. The results of molecular assays were negative when peripheral blood was used for PCR. Unfortunately, due to respective nature of the study, molecular tests on bone marrow samples were not repeated.

In conclusion, 2-CdA seems to be beneficial in some patients with advSM, however the response is incomplete and transient. No complete responses have been demonstrated so far. The recent approval of tyrosine kinase inhibitor-midostaurin may change our management with patients with advM [7]. Nevertheless, ORR was found to be similar to 2-CdA, but head-to-head study was not performed. The value of maintenance therapy or combination of 2-CdA with midostaurin require further studies.

Compliance with Ethical Standards

Conflict of interest All authors declare that they have no conflict of interest.

Informed consent Informed consent was obtained from all patients participated in the study.

Ethical approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

References

1. Akin C (2015) Cladribine for mastocytosis: benefits and risks. Blood 126:931–932
2. Alstadhaug KB, Fykse Halstensen R, Odeh F (2017) Progressive multifocal leukoencephalopathy in a patient with systemic mastocytosis treated with cladribine. J Clin Virol 88:17–20
3. Arock M, Valient P (2010) Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol 3:497–516
4. Barete S, Lortholary O, Damaj G, Hirsch I, Chandesris MO, Elie C, Hamidou M, Durieu I, Suarez F, Grosbois B, Limal N, Gyan E, Larroche C, Guillet G, Kahn JE, Casassus P, Amazzough K, Cognard-Biehler H, Georgin-Lavialle S, Lhermitte L, Fraitag S, Canioni D, Dubreuil P, Hermine O (2015) Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. Blood 126:1009–1016
5. Böhm A, Sonneck K, Gleixner KV, Schuch K, Pickl WF, Blatt K, Peter B, Herrmann H, Schernthaner GH, Pehamberger H, Rabitsch W, Sperr WR, Valient P (2010) In vitro and in vivo growth-inhibitory effects of cladribine on neoplastic mast cells exhibiting the imatinib-resistant KIT mutation D816V. Exp Hematol 38:744–755
6. Gotlib J, Gerds AT, Bose P, Castells MC, Deininger MW, Gojo I, Gundabolu K, Hobbs G, Jamieson C, McMahon B, Mohan SR, Oehler V, Oh S, Padron E, Pancari P, Papadantonakis N, Pardanani A, Podolsev N, Rampal R, Ranheim E, Rein L, Snyder DS, Stein BL, Talpaz M, Tshota S, Wadleigh M, Walsh K, Bergman MA, Sundar H (2018) Systemic mastocytosis, version 2.2019, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 16:1500–1537
7. Gotlib J, Kluin-Nelemans HC, George TI, Akin C, Sotlar K, Hermine O, Awan FT, Hexner E, Mauro MJ, Sternberg DW, Villeneuve M, Huntsman Labe D, Stanek EJ, Hartmann K, Horny HP, Valient P, Reiter A (2016) Efficacy and safety of midostaurin in advanced systemic mastocytosis. N Engl J Med 374:2530–2541
8. Gotlib J, Pardanani A, Akin C, Reiter A, George T, Hermine O, Kluin-Nelemans H, Hartmann K, Sperr WR, Brockow K, Schwartz LB, Orfao A, Deangelo DJ, Aroc M, Sotlar K, Horny HP, Mecalfee DD, Escribano L, Verstovsek S, Telferi A, Valient P (2013) International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis. Blood 121:2393–2401
9. Horny HP, Akin C, Arber DA, Peterson LC, Telferi A, Metcalfe DD, Bennett JM, Bain BJ, Escribano L, Valient P (2017) Mastocytosis. In: Swerdlow SH, et al. (eds) WHO classification of tumors of hematopoietic and lymphoid tissues. International Agency for Research and Cancer (IARC), Lyon, pp 62–69
10. Kluin-Nelemans HC, Oldhoff JM, Van Doormaal JJ, Van’t Wout JW, Verhoef G, Gerrits WB, van Dobbenburgh OA, Pasmans SG,
Fijnheer R (2003) Cladribine therapy for systemic mastocytosis. Blood 102:4270–4276
11. Lim KH, Pardanani A, Butterfield JH, Cy Li, Tefferi A (2009) Cytoreductive therapy in 108 adults with systemic mastocytosis: outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. Am J Hematol 84:790–794
12. Pardanani A (2019) Systemic mastocytosis in adults: 2019 update on diagnosis, risk stratification and management. Am J Hematol 94:363–377
13. Tefferi A, Cy Li, Butterfield JH, Hoagland HC (2001) Treatment of systemic mast-cell disease with cladribine. N Engl J Med 344:307–309
14. Valent P, Akin C, Hartmann K, Nilsson G, Reiter A, Hermine O, Sotlar K, Sperr WR, Escribano L, George TI, Khain-Nelemans HC, Ustun C, Triggiani M, Brockow K, Gotlib J, Orfao A, Schwartz LB, Broesby-Olsen S, Bindslev-Jensen C, Kovanen PT, Galli SJ, Austen KF, Arber DA, Horny HP, Arock M, Metcalfe DD (2017) Advances in the classification and treatment of mastocytosis: current status and outlook toward the future. Cancer Res 77:1261–1270

Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.